Visualitza per autor "Subbiah, Vivek"
Ara mostrant els elements 1-7 d 7
-
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Braña Garcia, Irene; Longhi, Alessandra; Awada, Ahmad; Subbiah, Vivek; Boni, Valentina; Delord, Jean-Pierre (American Association for Cancer Research, 2022-07-01) -
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Subbiah, Vivek; Kreitman, Robert; Wainberg, Zev A.; Gazzah, A.; Lassen, Ulrik; Stein, Alexander; Elez, Elena (Nature Portfolio, 2023-05) -
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
Fudio, Salvador; Tabernero Caturla, Josep; Chawla, Sant P.; Longo-Muñoz, Federico; Subbiah, Vivek; Moreno, Victor (Springer, 2021-01) -
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Cassier, Phillippe A.; Siena , Salvatore; Garralda Cabanas, Elena; Paz-Ares, Luis; Garrido, Pilar; Subbiah, Vivek (Nature Research, 2022-08) -
Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study
Griesinger, Frank; Baik, Christina; Tan, Daniel; Lee, Dae Ho; Curigliano, Giuseppe; Subbiah, Vivek; GARRALDA, Elena (Future Medicine, 2024-02) -
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, Frank; Thomas, M.; Baik, Christina; Tan, Daniel S. W.; Garralda Cabanas, Elena; Subbiah, Vivek; Curigliano, Giuseppe (Elsevier, 2022-11) -
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Drilon, Alexander; Gautschi, Oliver; Tomasini, Pascale; de Braud, Filippo G.; Alonso-Casal, Guzman; Solomon, Benjamin; Subbiah, Vivek (American Society of Clinical Oncology, 2023-01-10)